Camille Riff - Polyplus

Update on new viral vector strategies in gene therapy

February 25, 2021(4 years)

Polyplus-transfection initiates construction of Vectura, a new 4,000m2 facility

January 27, 2021(4 years)

Optimization of AAV process development: transfection matters

January 26, 2021(4 years)

Promising non-viral vector for efficient and versatile delivery of mRNA for antigen-specific immunotherapy

January 11, 2021(4 years)

Brexit announcement

December 17, 2020(4 years)

Advancing life science research by refining transfection: strategies and tips

December 9, 2020(4 years)

Expert podcast: Supporting COVID-19 vaccine strategies

December 8, 2020(4 years)

Viral vectors for gene therapy in a nutshell: AAVs, lentivirus, adenovirus and retrovirus

November 10, 2020(5 years)

Polyplus-transfection Names Mario Philips As Chief Executive Officer

November 3, 2020(5 years)

Expression of recombinant proteins

October 27, 2020(5 years)